Foto del docente

Luigi Bolondi

Retired Professor

Alma Mater Studiorum - Università di Bologna

Research

Keywords: microRNA treatment of HCC hepatocellular carcinoma ultrasound liver cirrhosis coelic disease

1) Molecular characterization of Hepatocellular Carcinoma for prognostic and therapeutic purposes. This objective is pursued by means of  "genome wide" analysis of transcriptome and microRNAome in HCC with different clinical patterns and investigation of NOTCH genes in hepatocarcinogenesis. 2) Optimization of use of new imaging technologies /US, RM, PET) for the early dagnosis and treatment of HCC. These objectives will be pursued by comparing innovative and experimental techniques, together with traditional imaging techniques. 3) Investigation of new treatments for intermediate and advanced HCC, not eligible for conventional treatments. Treatments actually under experimentation areIrinotecan, Yttrium 90 microspheres, angiogenesis and MAPK inhibitors. 4) Investigation of circulating markers for risk and aggressiveness of HCC. This study is carried outby means of MALDI-TOF analysis of serum proteome and circulating micro-RNA in patients with cirrhosis and HCC of different severity. 5) Evaluation of the different response to antiangiogenic treatment by elastosonography in animal models. 6) New diagnostic and therapeutic possibilities for celiac disease. 7) Study of the gut-liver axis alterations for the development of liver diseases and complications of cirrhosis.

1) Molecular characterization of Hepatocellular Carcinoma for prognostic and therapeutic purposes. This objective is pursued by means of  "genome wide" analysis of transcriptome and microRNAome in HCC with different clinical patterns and investigation of NOTCH genes in hepatocarcinogenesis. 2) Optimization of use of new imaging technologies /US, RM, PET) for the early dagnosis and treatment of HCC. These objectives will be pursued by comparing innovative and experimental techniques, together with traditional imaging techniques. 3) Investigation of new treatments for intermediate and advanced HCC, not eligible for conventional treatments. Treatments actually under experimentation areIrinotecan, Yttrium 90 microspheres, angiogenesis and MAPK inhibitors. 4) Investigation of circulating markers for risk and aggressiveness of HCC. This study is carried outby means of MALDI-TOF analysis of serum proteome and circulating micro-RNA in patients with cirrhosis and HCC of different severity. 5) Evaluation of the different response to antiangiogenic treatment by elastosonography in animal models. 6) New diagnostic and therapeutic possibilities for celiac disease. 7) Study of the gut-liver axis alterations for the development of liver diseases and complications of cirrhosis.